Abstract
Schizophrenia is a heterogeneous disease involving genetic and environmental factors. The frequency of structural brain abnormalities1, 2 or physical anomalies3supports a neurodevelopmental etiology, especially in early onset schizophrenia.4Brain-Derived-Neurotrophic-Factor (BDNF) is involved in the neurodevelopment of dopaminergic (DA)-related systems5, 6 and interacts with the meso-limbic DA systems,7, 8, 9, 10 involved in the therapeutic response to antipsychotic drugs11 and substance abuse.12 In addition, BDNF promotes and maintains dopamine D3 receptor (DRD3) expression.13 In a French Caucasian population, we found no statistical difference in allele or genotype distribution of the BDNF gene dinucleotide repeat polymorphism (166–174 bp)14 between the whole group of schizophrenic patients and controls. By contrast, an excess of the 172–176 bp alleles was found in patients with late onset, in neuroleptic-responding patients and in non-substance-abusing patients. BDNF gene variants thus appear to be associated with developmental features of schizophrenia. In addition, this association with good treatment responding was independent from the association found with the DRD3 BalI gene polymorphism in the same population.15 These results suggest an independent contribution of each gene to a treatment-sensitive form of schizophrenia.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Kovelman JA, Scheibel AB . A neurohistological correlate of schizophrenia Biol Psychiatry 1984; 19: 1601–1621
Weinberger DR, Lipska BK . Cortical maldevelopment, anti-psychotic drugs and schizophrenia: a search for common ground Schizophrenia Res 1995; 16: 87–110
Gualtieri CT, Adams A, Shen D, Loiselle D . Minor physical anomalies in alcoholic and schizophrenic adults and hyperactive and autistic children Am J Psychiatry 1982; 139: 640–643
Delisi LE, Hoff AL, Schwartz JE, Shields GW, Halthore SN, Gupta SM et al. Brain morphology in first episode schizophrenic-like psychotic patients: a quantitative magnetic resonance imaging study Biol Psychiatry 1991; 29: 159–175
Hyman C, Hofer M, Barde Y, Juhasz M, Yancopoulos G, SaL Squinto R . BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra Nature 1991; 350: 230–232
Thoenen H . Neurotrophins and neuronal plasticity Science 1995; 270: 593–598
Altar A, Boylan C, Jackson C, Hershenson S, Miller J, Wiegand S et al. Brain-derived neurotrophic factor augments rotational behavior and nigrostriatal dopamine turnover in vivo Proc Natl Acad Sci USA 1992; 89: 11347–11351
Blochl A, Sirrenberg C . Neurotrophins stimulate the release of dopamine from rat mesencephalic neurons via the Trk and p75Lntr receptors J Biol Chem 1996; 271: 21100–21107
Seroogy KB, Lundgren KH, Tran TMD, Guthrie KM, Isackson PJ, Gall C . Dopaminergic neurons in rat ventral midbrain express brain-derived neurotrophin factor and neurotrophin-3 mRNAs J Comp Neurol 1994; 342: 321–334
Altar CA, Cai N, Bliven T, Juhasz M, Conner JM, Acheson AL et al. Anterograde transport of brain-derived neurotrophic factor and its role in the brain Nature 1997; 389: 856–860
Carlsson A, Lindqvist M . Effect of chlorpromazine or haloperidol on the formation of 3-methoxytyramine and normetanephrine in mouse brain Acta Pharmacol Toxicol 1963; 20: 140–144
Di Chiara G, Imperato A . Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats Proc Natl Acad Sci USA 1988; 85: 5274–5278
Guillin O, Damier L, Griffon N, Diaz J, Carroll P, Schwartz J et al. Role of brain-derived neurotrophic factor in the control of D3 receptor expression Eur Neuropsychopharmacol 1999; 9, suppl 5: S184
Pröschel M, Saunders A, Roses A, Müller C . Dinucleotide repeat polymorphism at the human gene for the brain-derived neurotrophic factor (BDNF) Hum Mol Genet 1992; 1: 353
Krebs MO, Sautel F, Bourdel MC, Sokoloff P, Schwartz JC, Olie JP et al. Dopamine D3 receptor gene variants and substance abuse in schizophrenia Mol Psychiatry 1998; 3: 337–341
Hawi Z, Straub RE, O'Neill A, Kendler KS, Walsh D, Gill M . No linkage or linkage disequilibrium between brain-derived neurotrophic factor (BDNF) dinucleotide repeat polymorphism and schizophrenia in Irish families Psychiatry Res 1998; 81: 111–116
Sasaki T, Dai XY, Kuwata S, Fukuda R, Kunugi H, Hattori M et al. Brain-derived neurotrophic factor gene and schizophrenia in Japanese subjects Am J Med Genet) 1997; 74: 443–444
Gorwood P, Leboyer M, Jay M, Payan C, Feingold J . Gender and age at onset in schizophrenia: impact of family history Am J Psychiatry 1995; 152: 298–212
Numan S, Lane-Ladd S, Zhang L, Lundgren K, Russel D, Seroogy K et al. Differential regulation of neurotrophin and trk receptor mRNAs in catecholaminergic nuclei during chronic opiate treatment and withdrawal J Neurosci 1998; 18: 10700–10708
Segman R, Neeman T, Heresco-Levy U, Finkel B, Karagichey L, Schlafman M et al. Genotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia Mol Psychiatry 1999; 4: 247–253
Steen VM, Lovelie R, MacEwan T, McCreadue RG . Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients Mol Psychiatry 1997; 2: 139–145
Gurevich E, Bordelon Y, Shapiro R, Arnold S, Gur R, Joyce J . Mesolimbic dopamine D3 receptors and use of antipsychotics in patients with schizophrenia Arch Gen Psychiatry 1997; 54: 225–232
Sokoloff P, Giros B, Martres M, Bouthenet M, Schwartz J . Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics Nature 1990; 347: 146–151
Karayiorgou M, Gogos J . Dissecting the genetic complexity of schizophrenia Mol Psychiatry 1997; 2: 211–223
Endicott J, Spitzer RL . A diagnostic interview: a schedule for affective disorders and schizophrenia Arch Gen Psychiatry 1978; 35: 837–844
APA . Diagnostic and Statistical Manual of Mental Disorders. Revised, 3rd edn APA: Washington DC 1987
Kay SR, Fiszbein A, Opler LA . The positive and negative symptom scale (PANSS) Schizophr Bull 1987; 13: 261–276
Häfner H, Maurer K, Löffler W, Bustamante S, van der Heiden W, Riecher-Rössler A et al. Onset and early course of schizophrenia. In: Häfner H, Gattaz (eds) Search for the Causes of schizophrenia Springer Verlag: Berlin-Heidelberg-New York 1995; 43–66
Beratis S, Gabriel J, Holdas S . Age at onset in subtypes of schizophrenic disorders Schiz Bull 1994; 20: 287–296
May PR, Dencker SJ, Hubbard JW, Midha KK, Liberman RP . A systematic approach to treatment resistance in schizophrenic disorders. In: Dencker S, Kulhanel F (eds). Treatment Resistance in Schizophrenia Vieweg Verlag: Wiesbaden 1988
Acknowledgements
This work was promoted by INSERM. OG was supported by a Lundbeck grant and by the Fondation pour la Recherche Medicale. We wish to thank Marylis Corbex for her advice on statistical analysis.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Krebs, M., Guillin, O., Bourdel, M. et al. Brain Derived Neurotrophic Factor (BDNF) gene variants association with age at onset and therapeutic response in schizophrenia. Mol Psychiatry 5, 558–562 (2000). https://doi.org/10.1038/sj.mp.4000749
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.mp.4000749
Keywords
This article is cited by
-
Disclosing common biological signatures and predicting new therapeutic targets in schizophrenia and obsessive–compulsive disorder by integrated bioinformatics analysis
BMC Psychiatry (2023)
-
Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? a systematic review
BMC Psychiatry (2017)
-
From microRNA target validation to therapy: lessons learned from studies on BDNF
Cellular and Molecular Life Sciences (2015)
-
Association of the brain-derived neurotrophic factor val66met polymorphism with magnetic resonance spectroscopic markers in the human hippocampus: in vivo evidence for effects on the glutamate system
European Archives of Psychiatry and Clinical Neuroscience (2012)
-
Association of Disrupted in Schizophrenia 1 (DISC1) missense variants with ultra-resistant schizophrenia
The Pharmacogenomics Journal (2011)